丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke

目的 探讨心源性卒中患者使用丁苯酞对华法林抗凝作用的影响。 方法 前瞻性连续纳入成都医学院第一附属医院神经内科2019年6月—2021年12月期间收治的心源性卒中患者,患者入组后随机分为试验组(华法林+丁苯酞)和对照组(华法林)。监测两组患者的国际标准化比值(international standardized ratio,INR)变化情况并收集两组患者的临床资料,比较分析两组患者的INR达标时间、2周内达标率和90 d mRS评分的差异。 结果 本研究共纳入101例心源性卒中患者,试验组51例,对照组50例。两组基线数据(年龄、性别、用药前INR、收缩压和舒张压)差异无统计学意义,入...

Full description

Bibliographic Details
Main Author: 许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍
Format: Article
Language:zho
Published: Editorial Department of Chinese Journal of Stroke 2023-03-01
Series:Zhongguo cuzhong zazhi
Subjects:
Online Access:http://www.chinastroke.org.cn/CN/article/openArticlePDF.jsp?id=3762
_version_ 1797841913715359744
author 许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍
author_facet 许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍
author_sort 许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍
collection DOAJ
description 目的 探讨心源性卒中患者使用丁苯酞对华法林抗凝作用的影响。 方法 前瞻性连续纳入成都医学院第一附属医院神经内科2019年6月—2021年12月期间收治的心源性卒中患者,患者入组后随机分为试验组(华法林+丁苯酞)和对照组(华法林)。监测两组患者的国际标准化比值(international standardized ratio,INR)变化情况并收集两组患者的临床资料,比较分析两组患者的INR达标时间、2周内达标率和90 d mRS评分的差异。 结果 本研究共纳入101例心源性卒中患者,试验组51例,对照组50例。两组基线数据(年龄、性别、用药前INR、收缩压和舒张压)差异无统计学意义,入院时试验组的NIHSS评分[10(3.0~15.0)分 vs. 0(0~6.5)分,P<0.001],溶栓率(27.5% vs. 8.0%,P=0.011)与取栓率(25.5% vs. 2.0%,P=0.001)均高于对照组。试验组INR 2周内达标率与对照组相比差异无统计学意义(43.1% vs. 44.0%,P=0.930)。试验组达标时间较对照组明显缩短[(6.50±2.41)d vs.(9.64±4.40)d,P=0.015]。试验组90 d mRS评分与对照组相比,差异无统计学意义[3(0.5~4.0)分 vs. 2(0~3.0)分,P=0.175]。 结论 丁苯酞联合华法林治疗心源性卒中可能缩短华法林的达标时间,需进一步的研究来验证,但对于INR的达标率和90 d mRS评分无影响。 Abstract: Objective To investigate the effect of butylphthalide on warfarin anticoagulation in patients with cardiogenic stroke. Methods The patients with cardiogenic stroke admitted to the Department of Neurology of the First Affiliated Hospital of Chengdu Medical College from June 2019 to December 2021 were consecutively enrolled in this prospective study. All the patients were randomly divided into observation group (warfarin+butylphthalide) and control group (warfarin). The changes of international standardized ratio (INR) and clinical data of the two groups were collected. The time of INR reaching the target, the rate of reaching the target within 2 weeks and the mRS score at 90 days were compared and analyzed between the two groups. Results A total of 101 subjects were included in this study, with 51 cases in each group. There were no statistical differences in the baseline data of age, gender, INR before treatment, systolic and diastolic blood pressure between the two groups. The NIHSS score at admission [10 (3.0-15.0) vs. 0 (0-6.5), P<0.001], and the proportionof thrombolytic and thrombectomy patients (27.5% vs. 8.0%, P=0.011; 25.5% vs. 2.0%, P=0.001) were higher than that in the control group. There was no statistical difference in the rate of INR reaching the target within 2 weeks between the two groups (43.1% vs. 44.0%, P=0.930). The time to reach the target in the observation group was shorter than that in the control group [(6.50±2.41) d vs. (9.64±4.40) d, P=0.015]. There was no statistical difference in mRS score at 90 days between the two groups [3 (0.5-4.0) vs. 2 (0-3.0) , P=0.175]. Conclusions Butylphthalide combined with warfarin in treatment of cardiogenic stroke may shorten the time to reach the target of warfarin, which needs further study to verify, while it had no effect on the rate of INR reaching the target and 90-day mRS score.
first_indexed 2024-04-09T16:39:12Z
format Article
id doaj.art-82dab580a0304ef3ba9efb7c29a26bb0
institution Directory Open Access Journal
issn 1673-5765
language zho
last_indexed 2024-04-09T16:39:12Z
publishDate 2023-03-01
publisher Editorial Department of Chinese Journal of Stroke
record_format Article
series Zhongguo cuzhong zazhi
spelling doaj.art-82dab580a0304ef3ba9efb7c29a26bb02023-04-23T06:56:45ZzhoEditorial Department of Chinese Journal of StrokeZhongguo cuzhong zazhi1673-57652023-03-0118328829410.3969/j.issn.1673-5765.2023.03.008丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍0余建萍 yujianping@cmc.edu.cn目的 探讨心源性卒中患者使用丁苯酞对华法林抗凝作用的影响。 方法 前瞻性连续纳入成都医学院第一附属医院神经内科2019年6月—2021年12月期间收治的心源性卒中患者,患者入组后随机分为试验组(华法林+丁苯酞)和对照组(华法林)。监测两组患者的国际标准化比值(international standardized ratio,INR)变化情况并收集两组患者的临床资料,比较分析两组患者的INR达标时间、2周内达标率和90 d mRS评分的差异。 结果 本研究共纳入101例心源性卒中患者,试验组51例,对照组50例。两组基线数据(年龄、性别、用药前INR、收缩压和舒张压)差异无统计学意义,入院时试验组的NIHSS评分[10(3.0~15.0)分 vs. 0(0~6.5)分,P<0.001],溶栓率(27.5% vs. 8.0%,P=0.011)与取栓率(25.5% vs. 2.0%,P=0.001)均高于对照组。试验组INR 2周内达标率与对照组相比差异无统计学意义(43.1% vs. 44.0%,P=0.930)。试验组达标时间较对照组明显缩短[(6.50±2.41)d vs.(9.64±4.40)d,P=0.015]。试验组90 d mRS评分与对照组相比,差异无统计学意义[3(0.5~4.0)分 vs. 2(0~3.0)分,P=0.175]。 结论 丁苯酞联合华法林治疗心源性卒中可能缩短华法林的达标时间,需进一步的研究来验证,但对于INR的达标率和90 d mRS评分无影响。 Abstract: Objective To investigate the effect of butylphthalide on warfarin anticoagulation in patients with cardiogenic stroke. Methods The patients with cardiogenic stroke admitted to the Department of Neurology of the First Affiliated Hospital of Chengdu Medical College from June 2019 to December 2021 were consecutively enrolled in this prospective study. All the patients were randomly divided into observation group (warfarin+butylphthalide) and control group (warfarin). The changes of international standardized ratio (INR) and clinical data of the two groups were collected. The time of INR reaching the target, the rate of reaching the target within 2 weeks and the mRS score at 90 days were compared and analyzed between the two groups. Results A total of 101 subjects were included in this study, with 51 cases in each group. There were no statistical differences in the baseline data of age, gender, INR before treatment, systolic and diastolic blood pressure between the two groups. The NIHSS score at admission [10 (3.0-15.0) vs. 0 (0-6.5), P<0.001], and the proportionof thrombolytic and thrombectomy patients (27.5% vs. 8.0%, P=0.011; 25.5% vs. 2.0%, P=0.001) were higher than that in the control group. There was no statistical difference in the rate of INR reaching the target within 2 weeks between the two groups (43.1% vs. 44.0%, P=0.930). The time to reach the target in the observation group was shorter than that in the control group [(6.50±2.41) d vs. (9.64±4.40) d, P=0.015]. There was no statistical difference in mRS score at 90 days between the two groups [3 (0.5-4.0) vs. 2 (0-3.0) , P=0.175]. Conclusions Butylphthalide combined with warfarin in treatment of cardiogenic stroke may shorten the time to reach the target of warfarin, which needs further study to verify, while it had no effect on the rate of INR reaching the target and 90-day mRS score. http://www.chinastroke.org.cn/CN/article/openArticlePDF.jsp?id=3762丁苯酞华法林心源性卒中butylphthalidewarfarincardiogenic stroke
spellingShingle 许天铸, 彭诗语, 杨敏, 程航, 殷英, 刘勇, 刘明全, 余建萍
丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke
Zhongguo cuzhong zazhi
丁苯酞
华法林
心源性卒中
butylphthalide
warfarin
cardiogenic stroke
title 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke
title_full 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke
title_fullStr 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke
title_full_unstemmed 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke
title_short 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 Effect of Butylphthalein on Anticoagulation of Warfarin in Patients with Cardiogenic Stroke
title_sort 丁苯酞对华法林治疗心源性卒中患者抗凝作用的影响 effect of butylphthalein on anticoagulation of warfarin in patients with cardiogenic stroke
topic 丁苯酞
华法林
心源性卒中
butylphthalide
warfarin
cardiogenic stroke
url http://www.chinastroke.org.cn/CN/article/openArticlePDF.jsp?id=3762
work_keys_str_mv AT xǔtiānzhùpéngshīyǔyángmǐnchénghángyīnyīngliúyǒngliúmíngquányújiànpíng dīngběntàiduìhuáfǎlínzhìliáoxīnyuánxìngzúzhōnghuànzhěkàngníngzuòyòngdeyǐngxiǎngeffectofbutylphthaleinonanticoagulationofwarfarininpatientswithcardiogenicstroke